Boston Research & Management Inc. Reduces Holdings in Abbott Laboratories $ABT

Boston Research & Management modestly trimmed its Abbott Laboratories stake in Q2—selling 921 shares to hold 58,395 shares worth $7.94m—while a slate of other institutions made small adjustments, leaving hedge funds and institutions with roughly 75% ownership. Analysts remain broadly constructive: several firms upgraded or raised targets (William Blair strong-buy; Bernstein $150 PT; Goldman Sachs $157 PT; Evercore trimmed to $142) and MarketBeat shows a consensus “Moderate Buy” with an average target of $147 versus Friday’s close of $127.97, implying notable upside. Operationally Abbott reported Oct. 15 quarterly EPS of $1.30 in line with estimates and 6.9% revenue growth, issued FY25 EPS guidance of $5.12–5.18, trades at a P/E of ~16 with a $222.5bn market cap and a 1.8% yield, leaving it positioned as a broadly favored, moderately valued healthcare name with potential catalyst from analyst momentum and guidance execution.

Analysis

Boston Research & Management trimmed its Abbott Laboratories (ABT) position modestly in Q2, selling 921 shares to end the quarter with 58,395 shares valued at $7.942m; other institutions made only small adjustments and institutional/hedge fund ownership stands at 75.18%, indicating concentrated professional ownership and limited large-scale repositioning. Abbott reported Q3 results on Oct. 15 with EPS of $1.30 that met consensus and revenue of $11.37 billion versus a $11.40 billion estimate, with revenue up 6.9% year-over-year and prior-year EPS of $1.21, while management set FY25 guidance at $5.12–$5.18 (Market consensus 5.14). The company shows healthy profitability metrics—net margin 31.88% and ROE 17.78%—and a conservative balance sheet (debt/equity 0.25, current ratio 1.82); valuation sits at a market cap of $222.52bn, P/E 16.04 and PEG 2.36. Analysts remain broadly constructive: two Strong Buy, 17 Buy and four Hold generate a MarketBeat consensus of Moderate Buy with an average price target of $147 versus the recent open of $127.97, while the stock trades below its 50- and 200-day moving averages (50-day $129.95, 200-day $131.20) and yields 1.8% on a $2.36 annualized dividend (payout ratio 29.57%).

Key Decisions for Investors

• Consider a staged accumulation given the analyst consensus Moderate Buy and average $147 price target implies roughly 15% upside from the $127.97 open, supported by a P/E of ~16 and continued double-digit net margin
• Monitor upcoming quarterly revenue and margin prints and FY25 guidance execution closely since revenue missed estimates by $0.03bn despite EPS in-line, which could constrain near-term upside
• Because the share price sits below both the 50- and 200-day moving averages and analyst targets vary, use a phased entry or hedge (e.g., options) to limit downside risk while retaining upside exposure
• Income-focused investors may hold for the 1.8% yield and a sub-30% payout ratio but should re-rate positions if management materially revises FY25 EPS guidance or margin trends deteriorate